IP Library › Granted Patent US 12,247,051
Granted Patent B2
US 12,247,051 · App. 18/516,237 · Granted Mar 11, 2025

PCV2 ORF2 protein variant and virus like particles composed thereof

Inventors: Luis Alejandro Hernandez (Story City, IA); Christine Margaret Muehlenthaler (Ames, IA); Eric Martin Vaughn (Ames, IA); Gregory Haiwick (Ankeny, IA)
C07K14/005A61K39/12C12N7/00C12P21/02A61K39/00A61K2039/5256A61K2039/5258A61K2039/53C12N2710/14043C12N2750/10022C12N2750/10023C12N2750/10034C12N2750/10051C12N2799/026
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,051
App. No.
18/516,237
Granted
Mar 11, 2025
Kind
B2
Abstract

Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.

Claims (21)

1. A method of producing an immunogenic composition, comprising transfecting a cell with a plasmid, or an expression vector, wherein the plasmid or expression vector comprises a polynucleotide encoding:

a PCV2 ORF2 protein having

at amino acid position 59 an arginine residue or a lysine residue, and

at amino acid position 88 a proline residue, and

at amino acid position 151 a threonine residue, and

at amino acid position 206 an isoleucine residue, and

at amino acid position 232 an asparagine residue

and having at amino acid position 63 an amino acid residue other than an arginine residue or a lysine residue,

wherein the numbering of the amino acid positions refers to the amino acid sequence of wild type PCV2 ORF2 protein; and

wherein said immunogenic composition further contains a PCV2a ORF2 polypeptide.

2. A method of producing an immunogenic composition, comprising infecting a cell with a recombinant viral vector containing a polynucleotide encoding a PCV2 ORF2 protein having

at amino acid position 59 an arginine residue or a lysine residue, and

at amino acid position 88 a proline residue, and

at amino acid position 151 a threonine residue, and

at amino acid position 206 an isoleucine residue, and

at amino acid position 232 an asparagine residue

and having at amino acid position 63 an amino acid residue other than an arginine residue or a lysine residue,

wherein the numbering of the amino acid positions refers to the amino acid sequence of wild type PCV2 ORF2 protein; and

wherein said immunogenic composition further contains a PCV2a ORF2 polypeptide.

3. The method of claim 2 , wherein the cell is an insect cell.

4. The method of claim 2 , wherein the viral vector is a baculovirus.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Jan 5, 2024
From: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.; BOEHRINGER INGELHEIM VETMEDICA, INC.; BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
To: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Reel/Frame 066033/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2024
From: HERNANDEZ, LUIS ALEJANDRO; MUEHLENTHALER, CHRISTINE MARGARET; VAUGHN, ERIC MARTIN; HAIWICK, GREGORY
To: BOEHRINGER INGELHEIM VETMEDICA, INC.
Reel/Frame 066015/0682 →
Continuity (6)
Continuation 17215636 · Mar 29, 2021
Continuation 16154294 · Oct 8, 2018
Continuation 15295053 · Oct 17, 2016
Continuation 14504839 · Oct 2, 2014
Provisional Application 61885871 · Oct 2, 2013
Related Publication 20240076321A1 · Mar 7, 2024
References Cited (400)
US 2909462A · Warfield et al. · 1959 [cited by applicant]
US 5026543A · Rijke · 1991 [cited by applicant]
US 5155037A · Summers · 1992 [cited by applicant]
US 5202430A · Brian et al. · 1993 [cited by applicant]
US 5322774A · Peakman et al. · 1994 [cited by applicant]
US 5436001A · Kramer · 1995 [cited by applicant]
US 5476778A · Chladek et al. · 1995 [cited by applicant]
US 5565205A · Petersen et al. · 1996 [cited by applicant]
US 5580557A · Kramer · 1996 [cited by applicant]
US 5733555A · Chu · 1998 [cited by applicant]
US 5885823A · Knittel et al. · 1999 [cited by applicant]
US 5925359A · Van Woensel et al. · 1999 [cited by applicant]
US 5968525A · Fitzgerald et al. · 1999 [cited by applicant]
US 6217883B1 · Allan et al. · 2001 [cited by applicant]
US 6287856B1 · Poet et al. · 2001 [cited by applicant]
US 6294176B1 · Cochran et al. · 2001 [cited by applicant]
US 6368601B1 · Allan et al. · 2002 [cited by applicant]
US 6391314B1 · Allan et al. · 2002 [cited by applicant]
US 6497883B1 · Bublot et al. · 2002 [cited by applicant]
US 6517843B1 · Ellis et al. · 2003 [cited by applicant]
US 6660272B2 · Allan et al. · 2003 [cited by applicant]
US 6703023B1 · Jestin et al. · 2004 [cited by applicant]
US 6794163B2 · Liu et al. · 2004 [cited by applicant]
US 6808900B2 · Simonsen · 2004 [cited by applicant]
US 6841364B2 · Yuan et al. · 2005 [cited by applicant]
US 6846477B2 · Keich et al. · 2005 [cited by applicant]
US 6943152B1 · Audonnet et al. · 2005 [cited by applicant]
US 6953581B2 · Allan et al. · 2005 [cited by applicant]
US 7018638B2 · Chu et al. · 2006 [cited by applicant]
US 7109025B1 · Eloit et al. · 2006 [cited by applicant]
US 7122192B2 · Allan et al. · 2006 [cited by applicant]
US 7144698B2 · Wang et al. · 2006 [cited by applicant]
US 7148015B2 · Jestin et al. · 2006 [cited by applicant]
US 7169394B2 · Chu et al. · 2007 [cited by applicant]
US 7172899B2 · Liu et al. · 2007 [cited by applicant]
US 7179472B2 · Jestin et al. · 2007 [cited by applicant]
US 7192594B2 · Haines et al. · 2007 [cited by applicant]
US 7211379B2 · Ellis et al. · 2007 [cited by applicant]
US 7223407B2 · Jestin et al. · 2007 [cited by applicant]
US 7223594B2 · Jestin et al. · 2007 [cited by applicant]
US 7244433B2 · Jestin et al. · 2007 [cited by applicant]
US 7258865B2 · Jestin et al. · 2007 [cited by applicant]
US 7261898B2 · Jestin et al. · 2007 [cited by applicant]
US 7273617B2 · Yuan et al. · 2007 [cited by applicant]
US 7276353B2 · Meng et al. · 2007 [cited by applicant]
US 7279166B2 · Meng et al. · 2007 [cited by applicant]
US 7297537B2 · Jestin et al. · 2007 [cited by applicant]
US 7300785B2 · Meerts et al. · 2007 [cited by applicant]
US 7312065B2 · Roof et al. · 2007 [cited by applicant]
US 7314628B2 · Jestin et al. · 2008 [cited by applicant]
US 7323330B2 · Jestin et al. · 2008 [cited by applicant]
US 7335361B2 · Liao et al. · 2008 [cited by applicant]
US 7358075B2 · Allibert et al. · 2008 [cited by applicant]
US 7368117B2 · Fetzer et al. · 2008 [cited by applicant]
US 7371395B2 · Parisot et al. · 2008 [cited by applicant]
US 7390494B2 · Jestin et al. · 2008 [cited by applicant]
US 7405075B2 · Jestin et al. · 2008 [cited by applicant]
US 7407803B2 · Jestin et al. · 2008 [cited by applicant]
US 7425444B2 · Jestin et al. · 2008 [cited by applicant]
US 7700285B1 · Eichmeyer et al. · 2010 [cited by applicant]
US 7758865B2 · Jestin et al. · 2010 [cited by applicant]
US 7829101B2 · Eichmeyer et al. · 2010 [cited by applicant]
US 7829273B2 · Roof et al. · 2010 [cited by applicant]
US 7829274B2 · Fachinger et al. · 2010 [cited by applicant]
US 7833707B2 · Eichmeyer et al. · 2010 [cited by applicant]
US 7838213B2 · Roof et al. · 2010 [cited by applicant]
US 7838214B2 · Roof et al. · 2010 [cited by applicant]
US 7910306B2 · Eichmeyer et al. · 2011 [cited by applicant]
US 7914992B2 · Fachinger et al. · 2011 [cited by applicant]
US 7943298B2 · Fachinger et al. · 2011 [cited by applicant]
US 7951907B2 · Jestin et al. · 2011 [cited by applicant]
US 7968285B2 · Roof et al. · 2011 [cited by applicant]
US 8025888B2 · Eichmeyer et al. · 2011 [cited by applicant]
US 8119143B2 · Roof et al. · 2012 [cited by applicant]
US 8475805B2 · Fachinger et al. · 2013 [cited by applicant]
US 8496940B2 · Fachinger et al. · 2013 [cited by applicant]
US 8852613B2 · Ohnesorge et al. · 2014 [cited by applicant]
US 8865183B2 · Fachinger et al. · 2014 [cited by applicant]
US 9011868B2 · Roof et al. · 2015 [cited by applicant]
US 9011872B2 · Eichmeyer et al. · 2015 [cited by applicant]
US 9132187B2 · Fachinger et al. · 2015 [cited by applicant]
US 9505808B2 · Hernandez · 2016 [cited by examiner]
US 9517260B2 · Fachinger et al. · 2016 [cited by applicant]
US 9522182B2 · Fachinger et al. · 2016 [cited by applicant]
US 9555092B2 · Fachinger et al. · 2017 [cited by applicant]
US 9669087B2 · Roof et al. · 2017 [cited by applicant]
US 10131696B2 · Hernandez · 2018 [cited by examiner]
US 10555994B2 · Hernandez et al. · 2020 [cited by applicant]
US 10961281B2 · Hernandez · 2021 [cited by examiner]
US 11858963B2 · Hernandez · 2024 [cited by examiner]
US 20020146431A1 · Allan et al. · 2002 [cited by applicant]
US 20030096377A1 · Meng et al. · 2003 [cited by applicant]
US 20030170270A1 · Meng et al. · 2003 [cited by applicant]
US 20030199581A1 · Seligson et al. · 2003 [cited by applicant]
US 20030215455A1 · Reynolds et al. · 2003 [cited by applicant]
US 20040062775A1 · Jestin et al. · 2004 [cited by applicant]
US 20040076635A1 · Jestin et al. · 2004 [cited by applicant]
US 20040091502A1 · Jestin et al. · 2004 [cited by applicant]
US 20040132178A1 · Haines et al. · 2004 [cited by applicant]
US 20040161410A1 · Jestin et al. · 2004 [cited by applicant]
US 20040208901A1 · Ellsworth et al. · 2004 [cited by applicant]
US 20040253270A1 · Meng et al. · 2004 [cited by applicant]
US 20040258715A1 · Allan et al. · 2004 [cited by applicant]
US 20040265848A1 · Jestin et al. · 2004 [cited by applicant]
US 20050008651A1 · Jestin et al. · 2005 [cited by applicant]
US 20050013823A1 · Keich et al. · 2005 [cited by applicant]
US 20050031647A1 · Roof et al. · 2005 [cited by applicant]
US 20050058653A1 · Ellis et al. · 2005 [cited by applicant]
US 20050079185A1 · Parisot et al. · 2005 [cited by applicant]
US 20050084497A1 · Jestin et al. · 2005 [cited by applicant]
US 20050147966A1 · Meng et al. · 2005 [cited by applicant]
US 20050238662A1 · Jestin et al. · 2005 [cited by applicant]
US 20060002952A1 · Haines et al. · 2006 [cited by applicant]
US 20060029617A1 · Charreyre et al. · 2006 [cited by applicant]
US 20060083756A1 · Jestin et al. · 2006 [cited by applicant]
US 20060115489A1 · Birkett et al. · 2006 [cited by applicant]
US 20060204522A1 · Kroll et al. · 2006 [cited by applicant]
US 20060222659A1 · Jestin et al. · 2006 [cited by applicant]
US 20060228373A1 · Chu et al. · 2006 [cited by applicant]
US 20060233831A1 · Parisot et al. · 2006 [cited by applicant]
US 20060246425A1 · Allibert et al. · 2006 [cited by applicant]
US 20060286123A1 · Fetzer et al. · 2006 [cited by applicant]
US 20070196879A1 · Chabriere et al. · 2007 [cited by applicant]
US 20080181910A1 · Roof et al. · 2008 [cited by applicant]
US 20080226669A1 · Roof et al. · 2008 [cited by applicant]
US 20080233147A1 · Jestin et al. · 2008 [cited by applicant]
US 20080261887A1 · Roof et al. · 2008 [cited by applicant]
US 20080267995A1 · Roof et al. · 2008 [cited by applicant]
US 20080279875A1 · Roof et al. · 2008 [cited by applicant]
US 20080279876A1 · Roof et al. · 2008 [cited by applicant]
US 20080279889A1 · Roof et al. · 2008 [cited by applicant]
US 20090016992A1 · Eichmeyer et al. · 2009 [cited by applicant]
US 20090017064A1 · Wu et al. · 2009 [cited by applicant]
US 20090022751A1 · Eichmeyer et al. · 2009 [cited by applicant]
US 20090042245A1 · Eichmeyer et al. · 2009 [cited by applicant]
US 20100136060A1 · Kolb · 2010 [cited by applicant]
US 20100184016A1 · Lefebvre et al. · 2010 [cited by applicant]
US 20100189743A1 · Jestin et al. · 2010 [cited by applicant]
US 20110033495A1 · Roof et al. · 2011 [cited by applicant]
US 20110059126A1 · Kohler et al. · 2011 [cited by applicant]
US 20110091499A1 · Fachinger et al. · 2011 [cited by applicant]
US 20110217327A1 · Roof et al. · 2011 [cited by applicant]
US 20110274710A1 · Eichmeyer et al. · 2011 [cited by applicant]
US 20110305725A1 · Wu · 2011 [cited by applicant]
US 20130030320A1 · Maier · 2013 [cited by applicant]
US 20130115236A1 · Fachinger et al. · 2013 [cited by applicant]
US 20130230558A1 · Ohnesorge et al. · 2013 [cited by applicant]
US 20130273099A1 · Fachinger et al. · 2013 [cited by applicant]
US 20130302370A1 · Fachinger et al. · 2013 [cited by applicant]
US 20140322267A1 · Haiwick et al. · 2014 [cited by applicant]
US 20140377298A1 · Fachinger et al. · 2014 [cited by applicant]
US 20150093404A1 · Hernandez et al. · 2015 [cited by applicant]
US 20150174233A1 · Roof et al. · 2015 [cited by applicant]
US 20190023747A1 · Hernandez et al. · 2019 [cited by applicant]
US 20210221852A1 · Hernandez et al. · 2021 [cited by applicant]
CA 2264953A1 · 1998 [cited by applicant]
CA 2305623A1 · 1999 [cited by applicant]
CN 1579553A · 1920 [cited by applicant]
CN 1458167A · 2003 [cited by applicant]
CN 103122352A · 2013 [cited by applicant]
EP 1050584A1 · 2000 [cited by applicant]
EP 1073676A1 · 2001 [cited by applicant]
EP 1281760A1 · 2003 [cited by applicant]
EP 1386617A1 · 2004 [cited by applicant]
EP 3052516B1 · 2020 [cited by applicant]
JP 2002247979A · 2002 [cited by applicant]
JP 2005511075A · 2005 [cited by applicant]
WO 1989006972A1 · 1989 [cited by applicant]
WO 1990007935A1 · 1990 [cited by applicant]
WO 1991018627A1 · 1991 [cited by applicant]
WO 1992003157A1 · 1992 [cited by applicant]
WO 1993016726A2 · 1993 [cited by applicant]
WO 1996036356A1 · 1996 [cited by applicant]
WO 1999018214A1 · 1999 [cited by applicant]
WO 1999029717A3 · 1999 [cited by applicant]
WO 1999029871A3 · 1999 [cited by applicant]
WO 1999057141A1 · 1999 [cited by applicant]
WO 2000001409A2 · 2000 [cited by applicant]
WO 2000047756A1 · 2000 [cited by applicant]
WO 2000077188A2 · 2000 [cited by applicant]
WO 2000077216A2 · 2000 [cited by applicant]
WO 2001016330A2 · 2001 [cited by applicant]
WO 2001017556A1 · 2001 [cited by applicant]
WO 2001034191A1 · 2001 [cited by applicant]
WO 2001045735A2 · 2001 [cited by applicant]
WO 2001096377A2 · 2001 [cited by applicant]
WO 2002049666A2 · 2002 [cited by applicant]
WO 2002077210A2 · 2002 [cited by applicant]
WO 2003003941A2 · 2003 [cited by applicant]
WO 2003049703A2 · 2003 [cited by applicant]
WO 2003068993A1 · 2003 [cited by applicant]
WO 2004026336A1 · 2004 [cited by applicant]
WO 2004058142A2 · 2004 [cited by applicant]
WO 2004069184A2 · 2004 [cited by applicant]
WO 2005009462A2 · 2005 [cited by applicant]
WO 2005092069A2 · 2005 [cited by applicant]
WO 2005112995A1 · 2005 [cited by applicant]
WO 2006068663A2 · 2006 [cited by applicant]
WO 2006072065A2 · 2006 [cited by applicant]
WO 2006113372A2 · 2006 [cited by applicant]
WO 2006113373A2 · 2006 [cited by applicant]
WO 2007028823A1 · 2007 [cited by applicant]
WO 2007076520A2 · 2007 [cited by applicant]
WO 2007094893A2 · 2007 [cited by applicant]
WO 2008073464A2 · 2008 [cited by applicant]
WO 2008076915A2 · 2008 [cited by applicant]
WO 2008081015A1 · 2008 [cited by applicant]
WO 2008098909A1 · 2008 [cited by applicant]
WO 2009030684A2 · 2009 [cited by applicant]
WO 2009103037A1 · 2009 [cited by applicant]
WO 2011116094A2 · 2011 [cited by applicant]
WO 2012005732A1 · 2012 [cited by applicant]
WO 2012033911A2 · 2012 [cited by applicant]
WO 2014134561A2 · 2014 [cited by applicant]
WO 2014179200A1 · 2014 [cited by applicant]
WO 2015051099A1 · 2015 [cited by applicant]
WO 2015169732A1 · 2015 [cited by applicant]
WO 2016160761A2 · 2016 [cited by applicant]
Morris et al., “Characterization of Productive and Non-Productive ACMNPV Infection in Selected Insect Cell Lines”, Viro. 197, 1993, pp. 339-348. [cited by applicant]
Morris et al., “Promoter Influence on Baculovirus-Mediated Gene jExpression in Permissive and Nonpermissive Insect Cell Lines”, J. Virol., Dec. 1992, vol. 66, No. 12, pp. 7397-7405. [cited by applicant]
Mortola et al., “Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system”. FEBS Letters, vol. 576, 2004, pp. 174-178. [cited by applicant]
Muirhead, Mike, “Sources of information on PMWS/PDNS”. The Veterinary Record, vol. 150, No. 14, Apr. 6, 2002, p. 456. [cited by applicant]
Murakami et al., “Occurrence of Swine Salmonellosis in Postweaning Multisystemic Wasting Syndrome (PMWS) Affected Pigs Concurrently Infected with Porcine Reproduction and Respiratory Syndrome Virus (PRRSV)”. Journal of … [cited by applicant]
Nawagitgul et al., “Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein”. 2000, Journal of General Virology, vol. 81, pp. 2281-2287. [cited by applicant]
Nawagitgul et al., Modified Indirect Porcine Circovirus (PCV) Type 2-based and Recombinant Capsid Protein (ORF-2) Based Enzyme-Linked Immunosorbent Assays for Detection of Antibodies to PCV, Clinical and Diagnostic Labo… [cited by applicant]
Neutra et al., “Optimization of protein-production by the baculovirus expression vector system in shake flasks”. Applied Microbiology and Biotechnology Journal, vol. 37, No. 1, 1992, pp. 74-78. [cited by applicant]
Ng et al., “Extracellular self-assembly of virus-like particles from secreted recombinant polyoma virus major coat protein.” Protein Engineering, Design & Selection, vol. 20, No. 12, 2007, pp. 591-598. [cited by applicant]
Niewiesk, Stefan, “Maternal antibodies: clinical significance, mechansim of interference with immune responses, and possible vaccination strategies.” Frontiers in Immunology, vol. 5, Article 446, Sep. 2014, pp. 1-15. [cited by applicant]
Noad et al., “Virus-like particles as immunogens” Trends in Microbiology, vol. 11, No. 9, Sep. 2003, pp. 438-444. [cited by applicant]
O'Dea et al., “Porcine circovirus-associated disease in weaner pigs in Western Australia”. Australian Veterinary Journal, vol. 89, No. 4, Apr. 2011, pp. 122-130. [cited by applicant]
O'Neill, Kevin Charles, “Efficacy and impact of current commercial porcine circovirus type 2 (PCV2) vaccines in dams and growing pigs.” Graduate Theses and Dissertations, Graduate College, Iowa State University, Paper 1… [cited by applicant]
Ohnesorge et al., “Efficacy Studies—Efficacy evaluation of a mixed Mycoplasma hyopneumoniae bacterin and a porcine circovirus type 2 vaccine”. 2007, 1 page. [Accessed at http://www.ingelvacflex.co.uk/mycoflex/research/e… [cited by applicant]
Okuda, et al., “Experimental Reproduction of Post-Weaning Multisystemic Wasting Syndrome in Cesarean-Derived, Colostrum-Deprived Piglets Inoculated with Porcine Circovirus Type 2 (PCV2): Investigation of Quantitative PC… [cited by applicant]
Olejnik et al. “Effect of hyperosmolarity on recombinant protein productivity in baculovirus expression system.” Journal of Biotechnology, vol. 102, 2003, pp. 291-300. [cited by applicant]
Olvera et al., “Comparison of porcine circovirus type 2 load in serum quantified by a real time PCR in postweaning multisystemic wasting syndrome and porcine dermatitis and nephropathy syndrome naturally affected pigs”.… [cited by applicant]
Onuki et al., “Detection of Porcine Circovirus from Lesions of a Pig with Wasting Disease in Japan.” The Journal of Veterinary Medical Science, vol. 61, No. 10, Oct. 1999, pp. 1119-1123. [cited by applicant]
Opriessnig et al., “A commercial vaccine based on PCV2a and an experimental vaccine based on a variant mPCV2b are both effective in protecting pigs against challenge with a 2013 U.S. variant mPCV2b strain”. Vaccine, vol… [cited by applicant]
Opriessnig et al., “A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection”. Vaccine, vo… [cited by applicant]
Opriessnig et al., “Comparison of Molecular and Biological Characteristics of a Modified Live Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Vaccine (Ingelvac PRRS MLV), the Parent Strain of the Vaccine (AT… [cited by applicant]
Opriessnig et al., “Derivation of porcine circovirus type 2-negative pigs from positive breeding herds”. Journal of Swine Health and Production, vol. 12, No. 4, Jul. and Aug. 2004, pp. 186-191. [cited by applicant]
Opriessnig et al., “Differences in virulence among porcine circovirus type 2 isolates are unrelated to cluster type 2a or 2b and prior infection provides heterologous protection”. Journal of General Virology, vol. 89, N… [cited by applicant]
Opriessnig et al., “Effect of porcine circovirus type 2 (PCV2) vaccination on porcine reproductive and respiratory syndrome virus (PRRSV) and PCV2 coinfection”. Veterinary Microbiology, vol. 131, 2008, pp. 103-114. [cited by applicant]
Opriessnig et al., “Effect of porcine parvovirus vaccination on the development of PMWS in segregated early weaned pigs coinfected with type 2 porcine circovirus and porcine parvovirus”. Veterinary Microbiology, vol. 98… [cited by applicant]
Opriessnig et al., “Effect of Vaccination with Selective Bacterins on Conventional Pigs Infected with Type 2 Porcine Circovirus”. Veterinary Pathology, vol. 40, 2003, pp. 521-529. [cited by applicant]
Opriessnig et al., “Effects of the timing of the administration of Mycoplasma hyopneumoniae bacterin on the development of lesions associated with porcine circovirus type 2”. Veterinary Record, vol. 158, No. 5, Feb. 200… [cited by applicant]
Opriessnig et al., “Experimental Co-Infection with Porcine Circovirus Type 2 and [cited by applicant]
Opriessnig et al., “Experimental Reproduction of Postweaning Multisystemic Wasting Syndrome in Pigs by Dual Infection with Mycoplasma hyopneumoniae and Porcine Circovirus Type 2”. Veterinary Pathology, vol. 41, No. 6, N… [cited by applicant]
Opriessnig et al., “Influence of anti-PCV2 passively-acquired antibodies on efficacy of Suvaxyn® PCV2 vaccination in pigs experimentally-infected with PCV2.” American Association of Swine Veterinarians, 2007, pp. 299-30… [cited by applicant]
Opriessnig et al., “Porcine Circovirus Type 2 Infection Decreases the Efficacy of a Modified Live Porcine Reproductive and Respiratory Syndrome Virus Vaccine”, Clinical and Vaccine Immunology, Aug. 2006, vol. 13, No. 8,… [cited by applicant]
Ostanello et al., “Experimental infection of 3-week-old conventional colostrum-fed pigs with porcine circovirus type 2 and porcine parvovirus”. Veterinary Microbiology, vol. 108, No. 3-4, Jul. 2008, pp. 179-186. [cited by applicant]
Paterson, J.E., “Health and antimicrobial resistance”. Manipulating Pig Production X, Chapter 2, Proceedings of the Tenth Biennial Conference of the Australasian Pig Science Association (Inc.) (APSA) held in Christchurc… [cited by applicant]
Patterson et al., “Baculovirus and Insect Cell Gene Expression: Review of Baculovirus Biotechnology”. Environmental Health Perspectives, vol. 103, Nos. 7-8, Jul.-Aug. 1995, pp. 756-759. [cited by applicant]
Patterson et al., “Interlaboratory Comparison of Porcine Circovirus-2 Indirect Immunofluorescent Antibody Test and Enzyme-Linked Immunosorbent Assay Results on Experimentally Infected Pigs”. Journal of Veterinary Diagno… [cited by applicant]
Pejawar-Gaddy et al., “Generation of a Tumor Vaccine Candidate Based on Conjugation of a MUC1 Peptide to Polyionic Papillomavirus Virus-Like Particles (VLPs).” Cancer Immunogy, Immunotherapy, vol. 59, No. 11, Nov. 2010,… [cited by applicant]
Poljak et al., “Spread of porcine circovirus associated disease (PCVAD) in Ontario (Canada) swine herds: Part I. Exploratory spatial analysis”. BMC Veterinary Research, vol. 6, No. 59, 2010, pp. 1-15. [cited by applicant]
Polo et al., “Half-life of porcine antibodies absorbed from a colostrum supplement containing porcine immunoglobulins.” Journal of Animal Science, vol. 90, 2012, pp. 308-310. [cited by applicant]
Poppe et al., “ [cited by applicant]
Pyle et al., “Secretion of biologically active human proapolipoprotein A-I in a baculovirus-insect cell system: protection from degradation by protease inhibitors”. Journal of Lipid Research, vol. 36, 1995, pp. 2355-236… [cited by applicant]
Quintana et al., “Clinical and pathological observations on pigs with postweaning multisystemic wasting syndrome”. 2001, The Veterinary Record, vol. 149, pp. 357-361. [cited by applicant]
Ragona et al., “The Transcriptional Factor Egr-1 Is Synthesized by Baculovirus-Infected Insect Cells in an Active, DNA-Binding Form”. DNA and Cell Biology, vol. 10, No. 1, 1991, pp. 61-66. [cited by applicant]
Remington et al., “Active Immunizing Agents.” Remington: The Science and Practice of Pharmacy, Twentieth Edition, 2000, p. 1569. [cited by applicant]
Reynaud et al., “Comparison of Clinical, Lesional and Virological Signs in Pigs With and Without Experimental PMWS.” Proceedings of the 17th International Pig Veterinary Society Congress, Ames, lowa, USA, Jun. 2002, vol… [cited by applicant]
Riggs et al., “Protective Monoclonal Antibody Defines a Circumsporozoite-Like Glycoprotein Exoantigen of Cryptosporidium parvum Sporozoites and Merozoites”. The Journal of Immunology, vol. 158, 1997, pp. 1787-1795. [cited by applicant]
Robinson et al., “Immunofluorescence.” IHC Staining Methods, Fifth Edition, Chapter 10, 2009, pp. 61-65. [cited by applicant]
Rodríguez-Arrioja et al., “Dynamics of procine circovirus type 2 infection in a herd of pigs with postweaning multisystemic wasting syndrome”. American Journal of Veterinary Research, vol. 63, No. 3, Mar. 2002, pp. 354-… [cited by applicant]
Roesler et al., “Oral vaccination of pigs with an invasive gyrA-cpxA-rpoB [cited by applicant]
Rossow et al., “Experimental porcine reproductive and respiratory syndrome virus infection in one-, four-, and 10- week-old pigs.” Journal of Veterinary Diagnositc Investigations, vol. 6, 1994, pp. 3-12. [cited by applicant]
Rota et al., “Expression of influenza A and B virus nucleoprotein antigens in baculovirus.” Journal of General Virology, vol. 71, 1990, pp. 1545-1554. [cited by applicant]
Fenaux et al., “Immunogenicity and Pathogenicity of Chimeric Infectious DNA Clones of Pathogenic Porcine Circovirus Type 2 (PCV2) and Nonpathogenic PCV1 in Weanling Pigs”. Journal of Virology, vol. 77, No. 20, Oct. 2003… [cited by applicant]
Fort et al., “Porcine circovirus type 2 (PCV2) vaccination of conventional pigs prevents viremia against PCV2 isolates of different genotypes and geographic origins”. Vaccine, vol. 26, No. 8, 2008, pp. 1063-1071. [cited by applicant]
Gagrcin et al., “Complex of Swine Respiratory Diseases-Strategy of control in light of latest knowledge”. Veterinarski Glasnik, vol. 58, No. 7-8, 2004, pp. 409-418. [English Abstract at p. 417.]. [cited by applicant]
Genbank Accession No. AAC61738, Version AAC61738.1 GI:3661517, Sep. 29, 1998. [cited by applicant]
GenBank Accession No. AF201311, Direct Submission, submitted Feb. 23, 2000 in Mankertz et al., “Characterization of PCV-2 isolates from Spain, Germany and France”, Virus Research, vol. 66, No. 1, 2000, pp. 65-77, 2 page… [cited by applicant]
Genbank Accession# AAF87231.1, PCV2 ORF2 Protein, 2000. [cited by applicant]
Gerber et al., “Fetal infections and antibody profiles in pigs naturally infected with porcine circovirus type 2 (PCV2).” The Canadian Journal of Veterinary Research, vol. 76, 2012, pp. 38-44. [cited by applicant]
Gizurarson, Sveinbjörn, “Clinically Relevant Vaccine-Vaccine Interactions”. BioDrugs, vol. 9, No. 6, Jun. 1998, pp. 443-453. [cited by applicant]
Goldenthal et al., “Overview-Combination Vaccines and Simultaneous Administration: Past, Present, and Future.” Annals of the New York Academy of Sciences, vol. 754, 1995, pp. xi-xiv. [cited by applicant]
Grau-Roma et al., “Recent advances in the epidemiology, diagnosis and control of diseases caused by porcine circovirus type 2.” The Veterinary Journal, vol. 187, 2011, pp. 23-32. [cited by applicant]
Groner, et al., The Biology of Baculoviruses, vol. 1, Biological Properties and Moleculary Biology, 1986, Chapter 9, Specificity and Safety of Baculoviruses, pp. 177-202. [cited by applicant]
Gualandi et al., “The Ability by Different Preparations of Porcine Parvovirus to Enhance Humoral Immunity in Swine and Guinea Pigs”. Microbiologica, vol. 11, No. 4, 1988, pp. 363-369. [cited by applicant]
Gualandi et al., “The Response of Pregnant Gilts Previously Given an Inactivated Preparation of Porcine Parvovirus (PPV) to Challenge Infection with a Fully Virulent PPV”. Microbiologica, vol. 15, 1992, pp. 391-396. [cited by applicant]
Ha et al., “Outbreak of salmonellosis in pigs with postweaning multisystemic wasting syndrome”. Veterinary Record, vol. 156, No. 18, Apr. 2005, pp. 583-584. [cited by applicant]
Haake et al., “Influence of age on the effectiveness of PCV2 vaccination in piglets with high levels of maternally derived antibodies”. Veterinary Microbiology, vol. 168, 2014, pp. 272-280. [cited by applicant]
Haiwick et al., “Trivalent vaccine mixture protects against simultaneous challenge with M. hyopneumoniae, PCV2, and PRRS virus”. Allen D. Leman Swine Conference, 2010, p. 176. [cited by applicant]
Halbur et al., “Porcine Circovirus Associated Disease (PCVA) . . . a “Double Bogey”.” Carthage Veterinary Service ltd. 16th Annual Swine Conference, Jan. 1, 2006, 3 pages. [Accessed at http://www.prairieswine.com/porcin… [cited by applicant]
Halbur et al., “Update on Porcine Circovirus Type 2 (PCV2)-Associated Diseases.” Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, IA, 12th Annual Swine Disease Conference for Swine Prac… [cited by applicant]
Hallsworth et al., “Limits of life in MgCl2-containing environments: chaotropicity defines the window.” Environmental Microbiology, vol. 9, No. 3, 2007, pp. 801-813. [cited by applicant]
Hamel et al., “Nucleotide Sequence of Porcine Circovirus Associated with Postweaning Multisystemic Wasting Syndrome in Pigs”. Journal of Virology, vol. 72, No. 6, Jun. 1998, pp. 5262-5267. [cited by applicant]
Han et al., “Self-Assembly of the Recombinant Capsid Protein of a Bovine Norovirus (BoNV) into Virus-Like Particles and Evaluation of Cross-Reactivity of BoNV with Human Noroviruses.” Journal of Clinical Microbiology, v… [cited by applicant]
Harayama et al., “Maternal porcine circovirus type 2-memory T cells transfers to piglets through colostrums ingestion.” Proceedings of the 5th Asian Pig Veterinary Society Congress Mar. 7-9, 2011, Pattaya, Thailand, p. … [cited by applicant]
Harding et al. “Dual heterologous porcine circovirus genogroup 2a/2b infection induces sever disease in germ-free pigs.” Veterinary Microbiology, vol. 145, 2010 pp. 209-219. [cited by applicant]
Harding et al., “Postweaning multisystemic wasting syndrome: Epidemiology and clincial presentation.” Swine Health and Production, vol. 6, No. 6, 1998, pp. 249-254. [cited by applicant]
Harding et al., “Recognizing and diagnosing postweaning multisystemic wasting syndrome (PMWS)”. Swine Health and Production, vol. 5, No. 5, 1997, pp. 201-203. [cited by applicant]
Harding, John C. “Post Weaning Multisystemic Wasting Syndrome (PMWS): Preliminary Epidemiology and Clinical Findings.” Proceedings of the Western Canadian Association of Swine Practitioners, 1996 Annual Meeting, Oct. 19… [cited by applicant]
Harms et al., “Three cases of porcine respiratory disease complex associated with porcine circovirus type 2 infection”. Journal of Swine Health and Production, vol. 10, No. 1, 2002, pp. 27-30. [cited by applicant]
Haruna et al., “The role of immunostimulation in the development of postweaning multisystemic wasting syndrome in pigs under field conditions”. Canadian Journal of Veterinary Research, vol. 70, Oct. 2006, pp. 269-276. [cited by applicant]
Hesse et al., “Evidence for recombination between PCV2a and PCV2b in the field.” Virus Research, vol. 132, 2008, pp. 201-207. [cited by applicant]
Hilgers et al., “Alkyl-esters of polyacrylic acid as vaccine adjuvants”. Vaccine, vol. 16, No. 16, 1998, pp. 1575-1581. [cited by applicant]
HiMedia Laboratories Pvt. Ltd., “TNM-FH Insect Medium With [cited by applicant]
Hirai et al., “Dual infection with PCV-2 and porcine epidemic diarrhoea virus in neonatal piglets”. The Veterinary Record, vol. 148, 2001, pp. 482-484. [cited by applicant]
Hodgins et al., “Influence of age and maternal antibodies on antibody responses of neonatal piglets vaccinated against Mycoplasma hyopneumoniae.” Journal of Swine Health and Production, vol. 12, No. 1, Jan.-Feb. 2004, p… [cited by applicant]
Hoogland et al., “Effects of adjuvants on porcine circovirus type 2-associated lesions”. Journal of Swine Health and Production, vol. 14, No. 3, 2006, pp. 133-139. [cited by applicant]
Hu et al., “Baculovirus as a highly efficient expression vector in insect and mammalian cells.” Acta Pharmacologica Sinica, vol. 26, No. 4, Apr. 2005, pp. 405-416. [cited by applicant]
Huang et al., “Porcine circovirus type 2 (PCV2) infection decreases the efficacy of an attenuated classical swine fever virus (CSFV) vaccine”. Veterinary Research, vol. 42, 115, 2011, pp. 1-9. [cited by applicant]
Hulst et al., “Glycoprotein E1 of Hog Cholera Virus Expressed in Insect Cells Protects Swine from Hog Cholera.” Journal of Virology, vol. 67, No. 9, Sep. 1993, pp. 5435-5442. [cited by applicant]
Hüser et al., “Baculovirus Vectors: Novel Mammalian Cell Gene-Delivery Vehicles and Their Applications”. American Journal of Pharmacogenomics, vol. 3, No. 1, 2003, pp. 53-63. [cited by applicant]
Insel et al., “Potential Alterations in Immunogenicity by Combining or Simultaneously Administering Vaccine Components.” Annals of the New York Academy of Sciences, vol. 754, 1995, pp. 35-47. [cited by applicant]
Intervet Schering-Plough Animal Health, “Porcilis PRRS Data Sheet.” 2011, pp. 1-3. [Accessed at http://www.intervet.co.uk/Products_Public/Porcilis_PRRS/Product_Datasheet.aspx on Apr. 12, 2011.]. [cited by applicant]
Inumaru et al., “Expression of biologically active recombinant porcinee GM-CSF by baculovirus gene expression system”. 1998, Immunology and Cell Biology, vol. 76, pp. 195-201. [cited by applicant]
Invitrogen Life Technologies, “Growth and Maintenance of Insect Cell Lines”. Insect Cell Lines Manual, Version K, Jul. 12, 2002, pp. 1-34. [Accessed at http://www.med.unc.edu/pharm/sondeklab/Lab%20Resources/manuals/inse… [cited by applicant]
Invitrogen Life Technologies, “Guide to Baculovirus Express Vector Systems (BEVS) and Insect Cell Culture Techniques”. Feb. 27, 2002, pp. 1-130. [Accessed at https://tools.thermofisher.com/content/sfs/manuals/bevtest.pd… [cited by applicant]
Iowa State University, “Lyphoid Depletion: PCV2-Associated Lymphoid Depletion”., 2013, pp. 1-2. [Accessed at: http://vetmed.iastate.edu/research/labs/pcv2/pcv2-associated-disease/lymphoid-depleti . . . on Dec. 14, 2013]. [cited by applicant]
Jensen et al., “Distinction between Porcine Circovirus Type 2 Enteritis and Porcine Proliferative Enteropathy caused by Lawsonia intracellularis”. Journal of Comparative Pathology, vol. 135, 2006, pp. 176-182. [cited by applicant]
Jensen, Poul Moesgaard, “The Danish SPF-Sytem Developments and challenges in the future.” Quarisma-Workshop, May 16, 2013, pp. 1-18. [Accessed at: http://giqs.org/fileadmin/web_giqs/content/PDFs/PDFs_Quarisma/projektpla… [cited by applicant]
Jiang et al., “Expression, Self-Assembly, and Antigenicity of the Norwalk Virus Capsid Protein”. Journal of Virology, vol. 66, No. 11, Nov. 1992, pp. 6527-6532. [cited by applicant]
Jiang et al., “Synthesis of rotavirus-Like Particles in Insect Cells: Comparative and Quantitative Analysis”. Biotechnology and Bioengineering, vol. 60, No. 3, 1998, pp. 369-374. [cited by applicant]
Ju et al., “Immunogenicity of a recombinant pseudorabies virus expressing ORF1-ORF2 fusion protein of porcine circovirus type 2”. 2005, Veterinary Microbiology, vol. 109, pp. 179-190. [cited by applicant]
Kamstrup, et al., “Immunisation against PCV2 structural protein by DNA vaccination of mice”. 2004, Vaccine, vol. 22, pp. 1358-1361. [cited by applicant]
Kapust et al., “ [cited by applicant]
Kennedy et al., “Reproduction of Lesions of Postweaning Multisystemic Wasting Syndrome by Infection of Conventional Pigs with Porcine Circovirus Type 2 Alone or in a Combination with Porcine Parvovirus”. Journal of Comp… [cited by applicant]
Kim et al., “A comparison of the Lymphocyte Subpopulations of Pigs Experimentally Infected with Porcine Circovirus 2 and/or Parvovirus”. 2003, The Veterinary Journal, vol. 165, pp. 325-329. [cited by applicant]
Kim et al., “Association of Porcine Circovirus 2 with Porcine Respiratory Disese Complex”, The Vet. Jour., 2003, 166, pp. 251-256. [cited by applicant]
Kim et al., “Characterization of the Recombinant Proteins of Porcine Circovirus Type2 Field Isolate Expressed in the Baculovirus System”. 2002, Journal of Veterinary Science, vol. 3, No. 1, pp. 19-23. [cited by applicant]
Kim et al., “Efficacy of different disinfectants in vitro against porcine circovirus type 2”. The Veterinary Record, vol. 164, May 2009, pp. 599-600. [cited by applicant]
Kim et al., “Enteritis associated with procine circovirus 2 in pigs”. 2004, The Canadian Journal of Veterinary Research, vol. 68, pp. 218-221. [cited by applicant]
King et al., “Insect cell culture media and maintenance of insect cell lines.” The Baculovirus Expression System: A laboratory guide, First Edition, Springer-Science + Business Media, B.V., 1992, pp. 75-79. [cited by applicant]
Kiupel, M. “Postweaning Multisystemic Wasting Syndrome (PMWS) in pigs”. Production diseases in Farm Animals, 12th International Conference, Section D, Wageningen Academic Publishers, The Netherlands, 2006, pp. 74-89. [cited by applicant]
Kixmoller et al., “Reduction of PMWS-associated clinical signs and co-infections by vaccination against PCV2”. 2008, Vaccine, vol. 26, pp. 3443-3451. [cited by applicant]
Knudsen et al., “Child Mortality Following Standard, Medium or High Titre Measles Immunization in West Africa.” International Journal of Epidemiology, vol. 25, No. 3, 1996, pp. 665-673. [cited by applicant]
Kost, et al., “Recombinant baculoviruses as mammalian cell gene-delivery vectors”. Apr. 2002, Trends in Biotechnology, vol. 20, No. 4, pp. 173-180. [cited by applicant]
Kovacs et al., “The live attenuated bovine viral diarrhea virus components of a multi-valent vaccine confer protection against fetal infection”. Veterinary Microbiology, vol. 96, 2003, pp. 117-131. [cited by applicant]
Krakowka et al., “Activation of the Immune System is the Pivotal Event in the Production of Wasting Disease in Pigs Infected with Porcine Circovirus-2 (PCV-2)” Veterinary Pathology, vol. 38, 2001, pp. 31-42. [cited by applicant]
Krakowka et al., “Features of porcine circovirus-2 disease: correlations between lesions, amount and distribution of virus, and clinical outcome”. Journal of Veterinary Diagnostic Investigation, vol. 17, No. 3, May 2005… [cited by applicant]
Krakowka et al., “Viral Wasting Sydrome of Swine: Experimental Reproduction of Postweaning Multisystemic Wasting Syndrome in Gnotobiotic Swine by Coinfection with Porcine Circovirus 2 and Porcine Parvovirus.” Veterinary… [cited by applicant]
Kyriakis et al., “The Effects of Immuno-modulation of the Clinical and Pathological Expression of Postweaning Multisystemic Wasting Syndrome”. 2002, Journal of Comparative Pathology, vol. 126, pp. 38-46. [cited by applicant]
Kyriazakis et al., “The Maintenance of Health”. Whittemore's Science and Practice of Pig Production, Third Edition, Chapter 7, Blackwell Publishing Ltd., Oxford, UK, 2006, pp. 263-316. [cited by applicant]
Ladekjaer-Mikkelsen et al., “Reproduction of postweaning multisystemic wasting syndrome (PMWS) in immunostimulated and non-immunostimulated 3-week-old piglets experimentally infected with prcine circovirus type 2 (PCV2)… [cited by applicant]
Larochelle et al., “Comparative serologic and virologic study of commerical swine herds with and without postweaning multisystemic wasting syndrom.” The Canadian Journal of Veterinary Research, vol. 67, 2003, pp. 114-12… [cited by applicant]
Larochelle et al., “PCR Detection and Evidence of Shedding of Porcine Circovirus Type 2 in Boar Semen.” Journal of Clinical Microbiology, vol. 38, No. 12, Dec. 2000, pp. 4629-4632. [cited by applicant]
Lekcharoensuk et al., “Epitope Mapping of the Major Capsid Protein of Type 2 Porcine Circovirus (PCV2) by Using Chimeric PCV1 and PCV2”. Journal of Virology, vol. 78, No. 15, Aug. 2004, pp. 8135-8145. [cited by applicant]
Li et al., “Essential Elements of the Capsid Protein for Self-Assembly into Empty Virus-Like Particles of Hepatitis E Virus”. Journal of Virology, vol. 79, No. 20, Oct. 2005, pp. 12999-13006. [cited by applicant]
Li et al., “Expression and Self-Assembly of Empty Virus-Like Particle of Hepatitis E Virus”. Journal of Virology, vol. 71, No. 10, Oct. 1997, pp. 7207-7213. [cited by applicant]
Liesner et al., “Efficacy of Ingelvac CircoFLEX® in face of maternal antibodies in a field trial in France.” 2008 Allen D. Leman Swine Conference—Recent Research Reports, p. 9. [cited by applicant]
Liljeqvist et al., “Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines”. Journal of Biotechnology, vol. 73, 1999, pp. 1-33. [cited by applicant]
Lin et al., “Mycoplasma hyorhinis in Taiwan: Diagnosis and isolation of swine pneumonia pathogen”. Veterinary Microbiology, vol. 115, 2006, pp. 111-116. [cited by applicant]
Liu et al., “Bacterial Expression of an Immunologically Reactive PCV2 ORF2 Fusion Protein”. 2001, Protein Expression and Purification, vol. 21, pp. 115-120. [cited by applicant]
Liu et al., “Characterization of a Previously Unidentified Viral Protein in Porcine Circovirus Type 2-Infected Cells and Its Role in Virus-Induced Apoptosis”. Jul. 2005, Journal of Virology, vol. 79, No. 13, pp. 8262-82… [cited by applicant]
Liu et al., “Development of an ELISA Based on the Baculovirus-Expressed Capsid Protein of Porcine Circovirus Type 2 as Antigen”. Journal of Veterinary Medical Science, vol. 66, No. 3, 2004, pp. 237-242. [cited by applicant]
Liu et al., “Efficient production of type 2 porcine circovirus-like particles by a recombinant baculovirus”. Archives of Virology, vol. 153, 2008, pp. 2291-2295. [cited by applicant]
MacKinnon, J.D., “Vaccination Ramification? An Objective Look at How Vaccination Might Affect Post-Weaning Multisystemic Wasting Syndrome (PMWS) and Porcine Dermatitis and Nephropathy Syndrome (PDNS)”. 2003, The Pig Jou… [cited by applicant]
Maes et al., “Effect of vaccination against Mycoplasma hyopneumoniae in pig herds with an all-in/all-out production system”. Vaccine, vol. 17, 1999, pp. 1024-1034. [cited by applicant]
Magar et al., “Experimental Transmission of Porcine Circovirus Type 2 (PCV2) in Weaned Pigs: a Sequential Study.” Journal of Comparative Pathology, vol. 123, 2000, pp. 258-269. [cited by applicant]
Mahe et al., “Differential recognition of ORF2 protein from type 1 and type 2 porcine circoviruses and identification of immunorelevant epitopes”. 2000, Journal of General virology, vol. 81, pp. 1815-1824. [cited by applicant]
Maranga et al., “Virus-Like Particle Production at Low Multiplicities of Infection With the Baculovirus Insect Cell System”. Aug. 2003, Biotechnology and Bioengineering, vol. 84, No. 2, pp. 246-253. [cited by applicant]
Martelli et al., “One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions”. Veterinary Microbiology… [cited by applicant]
Mateu et al., “A Single Amino Acid substitution Affects Multiple Overlapping Epitopes in the Major Antigenic Site of Foot-and-Mouth Disease Virus of Serotype C,” Journal of General Virology, vol. 71, 1990, pp. 629-637. [cited by applicant]
McCall et al., “Improvements to the throughput of recombinant protein expression in the baculovirus/insect cell system.” Protein Expression and Purification, vol. 42, 2005, pp. 29-36. [cited by applicant]
McKeown et al., “Effects of Porcine Circovirus Type 2 (PCV2) Maternal Antibodies on Experimental Infection of Piglets with PCV2”. Clinical and Diagnostic Laboratory Immunology, vol. 12, No. 11, Nov. 2005, pp. 1347-1351. [cited by applicant]
McNair et al., “Interlaboratory testing of porcine sera for antibodies to porcine circovirus type 2.” Journal of Veterinary Diagnositc Investigation, vol. 16, 2004, pp. 164-166. [cited by applicant]
McNeilly et al., “Evaluation of a Porcine Circovirus Type 2-Specific Antigen-Captive Enzyme-Linked Immunosorbent Assay for the Diagnosis of Postweaning Multisystemic Wasting Syndrome in Pigs: Comparison with Virus Isola… [cited by applicant]
Meehan et al., “Characterization of novel circovirus DNAs associated with wasting syndromes in pigs”. Journal of General Virology, vol. 79, 1998, pp. 2171-2179. [cited by applicant]
Meerts et al., “Correlation between the prsence of neutralizing antibodies against porcine circovirus 2 (PCV2) and protection against replication of the virus and development of PCV2-associated disease.” BMV Veterinary … [cited by applicant]
Meerts et al., “Correlation Between Type of Adaptive Immune Response Against Porcine Circovirus Type 2 and Level of Virus Replication.” Viral Immunology, vol. 18, No. 2, 2005, pp. 333-341. [cited by applicant]
Merial Animal Health Ltd., “Progressis.” 2011, pp. 1-2. [Accessed at http://www.noahcompendium.co.uk/Merial_Animal_Health_Itd/documents/S3834.html on Apr. 12, 2011]. [cited by applicant]
Midwest Research Swine, “High Health Heard Status.” pp. 1-2. [Accessed at: http://midwestresearchswine.com/herd-health/high-health-herd-status/ on Jun. 27, 2016]. [cited by applicant]
Minion et al., “Then Genome Sequence of Mycoplasma hyopneumoniae Strain 232, the Agent of Swine Mycoplasmosis”. Nov. 2004, Journal of Bacteriology, vol. 186, No. 21, pp. 7123-7133. [cited by applicant]
Moraes et al., “ [cited by applicant]
Morales et al., “Serendipitous Discovery and X-Ray Structure of a Human Phosphate Binding Apolipoprotein”. Mar. 2006, Structure, vol. 14, pp. 601-609. [cited by applicant]
Takada-Iwao et al., “Porcine circovirus type 2 (PCV2) vaccination reduces PCV2 in a PCV2 and [cited by applicant]
Thacker et al. “Porcine Respiratory Disease Complex (PRDC)”. Thai Journal of Veterinary Medicine, vol. 32, Supp., 2002, pp. 126-134. [cited by applicant]
Thacker et al., “Effect of vaccination on the potentiation of porcine reproductive and respiratory syndrom virus (PRRSV)-induced pneumonia by Mycoplama hyopneumoniae”. Vaccine, vol. 18, 2000, pp. 1244-1252. [cited by applicant]
Thacker, Eileen L., “Diagnosis of Mycoplama hyopneumoniae”. Journal of Swine Health Production, vol. 12, No. 5, 2004, pp. 252-254. [cited by applicant]
Thacker, Eileen L., “Mycoplasmal Diseases”. Diseases of Swine, 9th Edition, Ch. 42, 2006, pp. 701-717. [cited by applicant]
Thomas et al., “Effect of PCV2 passive antibody levels on immunization with chimeric PCV1-2 vaccine and challenge with wild-type PCV2.” American Association of Swine Veterinarians, 2005, pp. 23-25. [cited by applicant]
Truong et al., “Identification of an immunorelevant ORF2 epitope from porcine circovirus type 2 as a serological marker for experimental and natural infection”. Archives of Virology, vol. 146, 2001, pp. 1197-1211. [cited by applicant]
UniProt Database Accession No. G3LHI3, by Cadar et al. “Detection of natural inter- and intra-genotype recombination events revealed by cap gene analysis and decreasing prevalence of PCV2 in wild boars.” Inectious Genet… [cited by applicant]
UniProt Database Accession No. O91862 submitted Nov. 1, 1998 by Meehan et al., Characterization of novel circovirus DNAs associated iwth wasting sydromes in pigs. Journal of General Virology, 1998; 79: 2171-2179, 1 page. [cited by applicant]
UniProt Database Accession No. Q9YTB6, Direct Submission, Wang et al., May 1, 1999 , 1 page. [cited by applicant]
UniProt Database Accession No. W0G6J4, by Shu et al., “Sequence analysis of complete genome of fifteen porcine circovirus type 2 strains in Jiangsu province”. Mar. 19, 2014, 1 page. [cited by applicant]
Urniza et al., “Duration of Immunity Study in Pigs Vaccinated with an Inactivated/Adjuvanted Vaccine ‘Chimeric Porcine Circovirus Type 1/Type 2’ in Front of a Challenge with PCV2 European Strain.” Proccedings of the 19t… [cited by applicant]
Vansickle, J., “Circovirus Grips Industry”. Jul. 15, 2006, National Hog Farmer. [cited by applicant]
Vasconcelos et al., “Swine and Poultry Pathogens: the Complete Genome Sequences of Two Strains of Mycoplasma hyopneumoniae and a Strain of Mycoplasma synoviae”. Aug. 2005, Journal of Bacteriology, vol. 187, No. 16, pp. … [cited by applicant]
Vicente et al., “Epidemiological Study on Porcine Circovirus type 2 (PCV2) Infection in the European Wild Boar ( [cited by applicant]
VIDO Swine Technical Group-Linking Knowledge to practical solutions “Vaccination Guidelines for Swine”. Jun. 2004, www.vido.org. [cited by applicant]
Vidor, E. “The Nature and Consequences of Intra- and Inter-Vaccine Interference.” Journal of Comparative Pathology, vol. 137, 2007, pp. S62-S66. [cited by applicant]
Vincent et al., “Dendritic Cells Harbor Infetious Porcine Circovirus Type 2 in the Abscence of Apparent Cell Modulation or Replication of the Virus”. Dec. 2003, Journal of Virology, vol. 77, No. 24, pp. 13288-13300. [cited by applicant]
Viscidi et al., “Age-Specific Seroprevalence of Merkel Cell Polyomavirus, BK Virus, and JC Virus.” Clinical and Vaccine Immunology, vol. 18, No. 10, Oct. 2011, pp. 1737-1743. [cited by applicant]
Walker, et al., “Development and application of a competitive enzyme-linked immunosorbent assay for the detection of serum antibodies to porcine circovirus type 2”. 2000, Journal of Veterinary Diagnostic Investigation, … [cited by applicant]
Wan et al., “Comprehensive Prevention and Control Techniques for Porcine Circovirus Type 2 Infection”. Chinese Swine Industry, No. 3, 2006, pp. 42-45. [cited by applicant]
Wang et al., “Construction and immunogenicity of recombinant adenovirus expressing the capsid protein of porcine circovirus 2 (PCV2) in mice”. Vaccine, vol. 24, 2006, pp. 3374-3380. [cited by applicant]
Warren et al., “Effect of Osmolality of the Cellular Microenvironment.” Encyclopedia of Industrial Biotechnology: Bioprocess, Bioseparation, and Cell Technology: Animal Cells, Hybridomas, Human Antibody Production, John… [cited by applicant]
Web site: “Does stress-free livestock mean safer food?” http://www.foodnavigator.com/Financial-Industry/Does-stress-free-livestock-mean-safer-food Accessed on: Jun. 4, 2004. [cited by applicant]
Weibel, Helen, “A field efficacy study with Enterisol® Ileitis and Ingelvac CircoFLEX® in Switzerland”. Universität Zürich, 2009, 1 page. [Accessed at: http://www.vet.uzh.ch/dissertationen/diss_anzeige.php?ID=724&sprach… [cited by applicant]
Weingartl et al., “Porcine circovirus structure and replication: a minireview”. Agriculture, vol. 1, 2002, pp. 11-14. [cited by applicant]
Wikipedia “Specific-pathogen-free”. Wikipedia, The Free Encyclopedia, May 28, 2016, at 04:21, pp. 1-3 [Accessed at https://en.wikipedia.org/w/index.php?title=Specific-pathogen-free&oldid=722441484 on Jun. 27, 2016. [cited by applicant]
Williams et al., “Combined vaccines and simultaneous administration: Current issues and perspectives”, Annals of the New York Academy of Sciences, vol. 754, 1995, pp. xi-xv, 35-47. [cited by applicant]
Wu et al., “Replication, Integration, and Packaging of Plasmid DNA following Cotransfection with Baculovirus Viral DNA”. Journal of Virology, vol. 73, No. 7, Jul. 1999, pp. 5473-5480. [cited by applicant]
Xia et al., “Preparation of and Immunity Tests with Canine Coronavirus BEI Inactivated Vaccine”. Chinese Journal of Veterinary Medicine, vol. 37, No. 3, 2001, pp. 37-38. [cited by applicant]
Yamada et al., “Evaluation of the Efficacy of Inactivated Vaccine against [cited by applicant]
Yamaji et al., “Efficient production of Japanese encephalitis virus-like particles by recombinant lepidopteran insect cells.” Applied Microbiology and Biotechnology, vol. 97, 2013, pp. 1071-1079. [cited by applicant]